TDOC Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Teladoc Health (TDOC)

Teladoc Health told investors in February 2026 that full-year revenue would reach $2.47 billion to $2.59 billion. Months later, the Company cut that outlook to $2.36 billion to $2.45 billion -- and the stock fell almost 30%.

NEW YORK--(BUSINESS WIRE)--Five months after guiding full-year 2026 consolidated revenue to a range of $2.47 billion to $2.59 billion, Teladoc Health (NYSE: TDOC) reduced that outlook to $2.36 billion to $2.45 billion, and shares fell nearly 30%. If you lost money holding Teladoc Health shares, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

On the February 25, 2026 fourth quarter earnings call, Chief Executive Officer Charles Divita stated, "We expect full-year consolidated revenue to be in the range of $2.47 billion to $2.59 billion, approximately leveled with 2025 at the midpoint." The revised range announced with second quarter 2026 results has a ceiling of only $2.447 billion.

“Moving to the BetterHelp segment,” CEO Divita noted the company was “guiding 2026 revenue down 7% to down 0.5% versus 2025, reflecting a moderating rate of decline versus both 2025 and 2024.” The revised range underpinning the company’s guidance reduction now projects revenue to be down 19% to 12.7%.

Shareholders who purchased TDOC and suffered a loss may request a free case evaluation here or call [phone].

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the TDOC Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Teladoc Health made materially false or misleading statements regarding its reported revenue figures and how those figures were characterized relative to guidance on earnings calls.

Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did TDOC stock drop? A: Shares fell nearly 30% after the Company reported Q2 2026 consolidated revenue of $606.9 million, below consensus expectations, and cut its full-year guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone].

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Attorney Advertising. Prior results do not guarantee similar outcomes.